Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GOP Lawmakers Seize On Adverse Event Analysis, Push For Mifeprex Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Bartlett (R-Md.) is seeking to revitalize support for the “RU-486 Suspension & Review Act.”

You may also be interested in...



Mifeprex Post-Marketing Restriction Compliance To Be Questioned By Rep. Souder

Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.

Mifeprex Post-Marketing Restriction Compliance To Be Questioned By Rep. Souder

Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.

Mifeprex “Black Box” Warning Revised On Reports Of Sepsis Deaths

Four deaths have been reported in California patients undergoing a medical abortion with Mifeprex (RU-486). Patients did not present with the typical symptoms of infection; a “high index of suspicion” is needed to rule out sepsis, FDA says.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel